India Pharma Outlook Team | Monday, 16 November 2026
The Zydus UK facility has come under US Food and Drug Administration (USFDA) scrutiny after an inspection at its LiqMeds manufacturing site concluded with four observations.
The inspection focused on the UK-based operation acquired by Zydus Lifesciences in 2023 for an upfront cost of GBP 68 million.
The company said it would work with the regulator to resolve the findings.
The development brings attention to the regulatory oversight of Zydus' overseas manufacturing operations and the integration of LiqMeds into its global oral liquid formulations business, which serves international markets.
Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships
Zydus Lifesciences disclosed that the USFDA inspection at LiqMeds, UK, concluded with four observations. The company stated that it would "closely work with the USFDA to address the observations expeditiously."
However, the company has not publicly specified the nature of the observations or disclosed a timeline for corrective action.
The four observations should not automatically be interpreted as a warning letter or a suspension of manufacturing operations. Their regulatory significance will depend on the findings and the company's subsequent response.
Zydus acquired the UK-headquartered LiqMeds Group in October 2023 through its wholly owned subsidiary, Zydus Pharmaceuticals UK Limited.
The acquisition involved:
LiqMeds operates through LM Manufacturing Limited, which has a manufacturing facility at Weedon, Northampton. The site supplies oral liquid products to the US and UK markets.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) lists the facility's authorized activities, including non-sterile liquid manufacturing, packaging and quality-control testing.
The Zydus UK facility operates within a regulatory environment involving both UK and US requirements. Its GMP compliance record lists the March 30, 2026 inspection as the most recent.
While the MHRA oversees manufacturing authorization and GMP compliance in the UK, the USFDA independently evaluates facilities supplying medicines to the American market.
For Zydus, addressing the latest observations will be important for maintaining regulatory readiness across its international oral liquid manufacturing operations.